Cart
sales@molnova.com
Home - Products - Apoptosis - IL Receptor - Tralokinumab

Tralokinumab

CAS No. 1044515-88-9

Tralokinumab( —— )

Catalog No. M36676 CAS No. 1044515-88-9

Tralokinumab is a fully human IgG4 monoclonal antibody with a high affinity for IL-13 alone.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 549 In Stock
10MG 867 In Stock
25MG 1283 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    Tralokinumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Tralokinumab is a fully human IgG4 monoclonal antibody with a high affinity for IL-13 alone.
  • Description
    Tralokinumab, a fully human IgG4 monoclonal antibody, specifically binds with high affinity to IL-13 alone, preventing its interaction with the receptor and subsequent downstream signalling. Tralokinumab can be used for the research of the atopic dermatitis (AD).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    IL Receptor
  • Recptor
    IL Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1044515-88-9
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. A Wollenberg, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021 Mar;184(3):437-449.?
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • Canakinumab

    Canakinumab (ACZ885) is a recombinant human IL-1β-targeting monoclonal antibody that inhibits human and chorioallantoic monkey IL-1β with IC50 values of 43.6 and 40.8 pM, respectively.

  • IL-15-IN-1

    IL-15-IN-1 is a selective?and potent Interleukin 15 (IL-15) inhibitor, inhibiting the proliferation of IL-15-dependent cells (IC50: 0.8 μM).

  • Nodosin

    Nodosin has an anti-inflammatory function via inhibition of IL-2. Nodosin perfusion provides a potential protective effect by inducing HO-1 expression to attenuate ischemia/reperfusion injury in liver transplantation.

Sign In Join Free